News

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the ...
Eli Lilly: The Best Growth Prospects Come At A Price
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
WFYI22h
Senators raise questions about deals between telehealth and drug companies
Lawmakers warn the arrangement Eli Lilly and Pfizer have with telehealth platforms may lead to conflicts of interest, subpar ...
PharmExec4d
Eli Lilly and Company Acquires Vere Therapeutics to Further Develop One-Time Cardiovascular Treatments
Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...
Lilly's cancer drug more effective than AbbVie's in head-to-head study
Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...
Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer
We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company ...
Eli Lilly: The Worst May Be Already Over (Earnings Preview)
Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.